Share on LinkedInShare on LinkedIn

ARTICLE · 29 APRIL 2014

Delhi High Court’s Decision On Teva Pharmaceutical’s Plaint Against Natco

S&A Law Offices
S&A Law Offices
Contributor
S&A Law Offices

S&A Law Offices

S&A Law Offices is a full-service law firm headquartered in Delhi NCR. The firm has 300+...

View firm profile
Explore more from S&A Law Offices

The Delhi High Court has returned Teva’s plea against NATCO seeking permanent injunction for restraining the manufacture of Glatiramer Acetate for sale in the US.

IndiaIntellectual Property

The Delhi High Court in its recent judgment1 has returned Teva Pharmaceutical's (the Plaintiffs) plea against NATCO (the Defendant) seeking permanent injunction for restraining NATCO from manufacturing Glatiramer Acetate product (Copaxone) for sale in the US. The main reason for the return of plaint as stated in the decision is that the pleadings relating to the product copaxone being sold in Delhi or elsewhere, or the possibility of copaxone being launched in Delhi or elsewhere do not fall into the ambit of the jurisdiction of Delhi High Court. Copaxone (Glatiramer Acetate or Copolymer 1) is used in the treatment of multiple sclerosis.

THE 2007 SUIT

Teva Pharmaceuticals Industries Ltd ('Teva'), Yeda Research and Development Co.Ltd ('Yeda') and Regent Drugs Ltd ('RDL') filed a suit (CS (OS) No. 1708 of 2007) against NATCO in Delhi High Court restraining the Defendant from infringement of the Indian Patent No.190759 and the rights associated with 'Glatimer'.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from